JP2011046732A5 - - Google Patents

Download PDF

Info

Publication number
JP2011046732A5
JP2011046732A5 JP2010243125A JP2010243125A JP2011046732A5 JP 2011046732 A5 JP2011046732 A5 JP 2011046732A5 JP 2010243125 A JP2010243125 A JP 2010243125A JP 2010243125 A JP2010243125 A JP 2010243125A JP 2011046732 A5 JP2011046732 A5 JP 2011046732A5
Authority
JP
Japan
Prior art keywords
cdr
amino acid
acid sequence
seq
adjacent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010243125A
Other languages
Japanese (ja)
Other versions
JP5162644B2 (en
JP2011046732A (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2011046732A publication Critical patent/JP2011046732A/en
Publication of JP2011046732A5 publication Critical patent/JP2011046732A5/ja
Application granted granted Critical
Publication of JP5162644B2 publication Critical patent/JP5162644B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (18)

モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメインとして以下のアミノ酸配列The monoclonal antibody or Fab fragment thereof has the following amino acid sequence as a heavy chain variable domain:
EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH（配列番号３１）EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPKVGCSWSKVLVVSL
を含み、Including
軽鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequence as the light chain variable domain
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC（配列番号２８）；DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQTYVSVTLTLS

DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGAGSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (配列番号３３)；DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGAGSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQTYVSLTLKTS

DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCKQGYANPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC （配列番号３０）；DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCKQGYANPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQGNDSQESVSLVSTKDSTY
又はOr
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYGNPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC（配列番号３２）DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYGNPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYEKAKVQWKVHKSSTLS
の一つを含んでなる、薬剤。A drug comprising one of the following: モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、The monoclonal antibody or Fab fragment thereof is
軽鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequence as the light chain variable domain
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCKQGFANPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (配列番号３４)DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCKQGFANPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQGNKASDY
を含み、Including
重鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequences as heavy chain variable domains
EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGVTPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH (配列番号３５)EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGVTPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPKVGCSWK
又はOr
EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGVTPAGGYTAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH (配列番号３６)EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGVTPAGGYTAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPKVGCSWK
を含む、薬剤。Including drugs. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、The monoclonal antibody or Fab fragment thereof is
重鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequences as heavy chain variable domains
EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH（配列番号３８）EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPKVGCSWSSVLVVSL
を含み、Including
軽鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequence as the light chain variable domain
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC（配列番号３７)DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNACLSGSSDSTYTY
又はOr
DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC（配列番号３９)DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQGNKASDY
を含む、薬剤。Including drugs. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、The monoclonal antibody or Fab fragment thereof is
重鎖可変ドメインとして以下のアミノ酸配列  The following amino acid sequences as heavy chain variable domains
EVQLVESGGGLVQPGGSLRLSCAASGFSINGSWIFWVRQAPGKGLEWVGAIWPFGGYTHYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH（配列番号４１）EVQLVESGGGLVQPGGSLRLSCAASGFSINGSWIFWVRQAPGKGLEWVGAIWPFGGYTHYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAKLCGCVKDYFPVVSGT
を含み、Including
さらに軽鎖可変ドメインとして以下のアミノ酸配列  Furthermore, the following amino acid sequence as a light chain variable domain
DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC（配列番号４０）DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQGNKASDY
を含む、薬剤。Including drugs. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＤＹＷＩＨ（配列番号２６１）を含み、(A) comprising CDR-H1 adjacent amino acid sequence DYWIH (SEQ ID NO: 261),
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＧＩＴＰＡＧＧＹＴＹＹＡＤＳＶＫＧ（配列番号４７４）を含み、(B) comprising the amino acid sequence GITPAGGYTYYADSVKG (SEQ ID NO: 474) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＦＶＦＦＬＰＹＡＭＤＹ（配列番号４７５）を含み、(C) comprising the amino acid sequence FVFFLPYAMDY (SEQ ID NO: 475) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＤＶＳＴＡＶＡ（配列番号４８）を含み、(D) comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO: 48) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＳＡＳＦＬＹＳ（配列番号４９）を含み、(E) comprising the amino acid sequence SASFLYS (SEQ ID NO: 49) to which CDR-L2 is adjacent;
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＳＹＴＴＰＰＴ（配列番号３６３）を含む、薬剤。(F) A drug comprising the amino acid sequence QQSYTTPPT (SEQ ID NO: 363) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＤＹＷＩＨ（配列番号２６１）を含み、(A) comprising CDR-H1 adjacent amino acid sequence DYWIH (SEQ ID NO: 261),
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＧＩＴＰＡＧＧＹＴＹＹＡＤＳＶＫＧ（配列番号４７４）を含み、(B) comprising the amino acid sequence GITPAGGYTYYADSVKG (SEQ ID NO: 474) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＦＶＦＦＬＰＹＡＭＤＹ（配列番号４７５）を含み、(C) comprising the amino acid sequence FVFFLPYAMDY (SEQ ID NO: 475) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＤＶＳＴＡＶＡ（配列番号４８）を含み、(D) comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO: 48) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＳＡＳＦＬＹＳ（配列番号４９）を含み、(E) comprising the amino acid sequence SASFLYS (SEQ ID NO: 49) to which CDR-L2 is adjacent;
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＫＱＧＹＡＮＰＷＴ（配列番号１４３）を含む、薬剤。(F) A drug comprising the amino acid sequence KQGYANPWT (SEQ ID NO: 143) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＤＹＷＩＨ（配列番号２６１）を含み、(A) comprising CDR-H1 adjacent amino acid sequence DYWIH (SEQ ID NO: 261),
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＧＩＴＰＡＧＧＹＴＹＹＡＤＳＶＫＧ（配列番号４７４）を含み、(B) comprising the amino acid sequence GITPAGGYTYYADSVKG (SEQ ID NO: 474) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＦＶＦＦＬＰＹＡＭＤＹ（配列番号４７５）を含み、(C) comprising the amino acid sequence FVFFLPYAMDY (SEQ ID NO: 475) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＤＶＳＴＡＶＡ（配列番号４８）を含み、(D) comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO: 48) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＳＡＳＦＬＹＳ（配列番号４９）を含み、(E) comprising the amino acid sequence SASFLYS (SEQ ID NO: 49) to which CDR-L2 is adjacent;
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＧＹＧＮＰＦＴ（配列番号５２）を含む、薬剤。(F) A drug comprising the amino acid sequence QQGYGNNPFT (SEQ ID NO: 52) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＤＹＷＩＨ（配列番号２６１）を含み、(A) comprising CDR-H1 adjacent amino acid sequence DYWIH (SEQ ID NO: 261),
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＧＩＴＰＡＧＧＹＴＹＹＡＤＳＶＫＧ（配列番号４７４）を含み、(B) comprising the amino acid sequence GITPAGGYTYYADSVKG (SEQ ID NO: 474) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＦＶＦＦＬＰＹＡＭＤＹ（配列番号４７５）を含み、(C) comprising the amino acid sequence FVFFLPYAMDY (SEQ ID NO: 475) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＤＶＳＴＡＶＡ（配列番号４８）を含み、(D) comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO: 48) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＳＡＳＦＬＹＳ（配列番号４９）を含み、(E) comprising the amino acid sequence SASFLYS (SEQ ID NO: 49) to which CDR-L2 is adjacent;
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＧＡＧＳＰＬＴ（配列番号６８）を含む、薬剤。(F) A drug comprising the amino acid sequence QQGASPLT (SEQ ID NO: 68) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＡＳＷＩＨ（配列番号９３６）を含み、(A) comprising CDR-H1 adjacent amino acid sequence ASWIH (SEQ ID NO: 936);
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＡＩＹＰＹＳＧＹＴＮＹＡＤＳＶＫＧ（配列番号９４１）を含み、(B) comprising the amino acid sequence AIYPYPSGYTNYADSVKG (SEQ ID NO: 941) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＷＧＨＳＴＳＰＷ（配列番号９３１）を含み、(C) comprising the amino acid sequence WGHSTSPW (SEQ ID NO: 931) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＤＶＳＴＡＶＡ（配列番号８５）を含み、(D) comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO: 85) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＳＡＳＦＬＹＳ（配列番号８６）を含み、(E) comprising CDR-L2 adjacent amino acid sequence SASFLYS (SEQ ID NO: 86),
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＳＹＴＴＰＰＴ（配列番号８７）を含む、薬剤。(F) A drug comprising the amino acid sequence QQSYTTPPT (SEQ ID NO: 87) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＧＳＷＩＦ（配列番号９３８）を含み、(A) comprising CDR-H1 adjacent amino acid sequence GSWIF (SEQ ID NO: 938),
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＧＡＩＷＰＦＧＧＹＴＨ（配列番号９３９）を含み、(B) comprising the amino acid sequence GAIWPFGGGTH (SEQ ID NO: 939) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＷＧＨＳＴＳＰＷ（配列番号９３１）を含み、(C) comprising the amino acid sequence WGHSTSPW (SEQ ID NO: 931) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＶＩＲＲＳＬＡ（配列番号１１７）を含み、(D) comprising the amino acid sequence RASQVIRRSLA (SEQ ID NO: 117) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＡＡＳＮＬＡＳ（配列番号１１８）を含み、(E) comprising the amino acid sequence AASNLAS (SEQ ID NO: 118) adjacent to CDR-L2,
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＳＮＴＳＰＬＴ（配列番号１１９）を含む、薬剤。(F) A drug comprising the amino acid sequence QQSNTSPLT (SEQ ID NO: 119) to which CDR-L3 is adjacent. モノクローナル抗体又はそのＦａｂ断片を含む、ヒト又はマウスの血管透過性を抑制するための薬剤であって、An agent for suppressing vascular permeability in humans or mice, comprising a monoclonal antibody or a Fab fragment thereof,
該モノクローナル抗体又はそのＦａｂ断片は、重鎖可変ドメイン及び軽鎖可変ドメインを含んでなり、該重鎖可変ドメインがＣＤＲ−Ｈ１、ＣＤＲ−Ｈ２及びＣＤＲ−Ｈ３を含み、The monoclonal antibody or Fab fragment thereof comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising CDR-H1, CDR-H2, and CDR-H3;
（ａ）ＣＤＲ−Ｈ１が近接するアミノ酸配列ＡＳＷＩＨ（配列番号９３６）を含み、(A) comprising CDR-H1 adjacent amino acid sequence ASWIH (SEQ ID NO: 936);
（ｂ）ＣＤＲ−Ｈ２が近接するアミノ酸配列ＡＩＹＰＹＳＧＹＴＮＹＡＤＳＶＫＧ（配列番号９４１）を含み、(B) comprising the amino acid sequence AIYPYPSGYTNYADSVKG (SEQ ID NO: 941) to which CDR-H2 is adjacent;
（ｃ）ＣＤＲ−Ｈ３が近接するアミノ酸配列ＷＧＨＳＴＳＰＷ（配列番号９３１）を含み、(C) comprising the amino acid sequence WGHSTSPW (SEQ ID NO: 931) to which CDR-H3 is adjacent;
該軽鎖可変ドメインがＣＤＲ−Ｌ１、ＣＤＲ−Ｌ２及びＣＤＲ−Ｌ３を含み、The light chain variable domain comprises CDR-L1, CDR-L2 and CDR-L3;
（ｄ）ＣＤＲ−Ｌ１が近接するアミノ酸配列ＲＡＳＱＶＩＲＲＳＬＡ（配列番号１１７）を含み、(D) comprising the amino acid sequence RASQVIRRSLA (SEQ ID NO: 117) to which CDR-L1 is adjacent;
（ｅ）ＣＤＲ−Ｌ２が近接するアミノ酸配列ＡＡＳＮＬＡＳ（配列番号１１８）を含み、(E) comprising the amino acid sequence AASNLAS (SEQ ID NO: 118) adjacent to CDR-L2,
（ｆ）ＣＤＲ−Ｌ３が近接するアミノ酸配列ＱＱＳＮＴＳＰＬＴ（配列番号１１９）を含む、薬剤。(F) A drug comprising the amino acid sequence QQSNTSPLT (SEQ ID NO: 119) to which CDR-L3 is adjacent. 前記ヒト又はマウスは癌、または眼の血管新生に起因する疾患を患っている、請求項１から１１の何れか一項に記載の薬剤。The drug according to any one of claims 1 to 11, wherein the human or mouse suffers from cancer or a disease caused by ocular neovascularization. 癌が、乳癌、大腸癌、非小細胞性肺癌、非ホジキンリンパ腫（ＮＨＬ）、腎臓癌、前立腺癌、肝臓癌、頭頸部癌、黒色腫、卵巣癌、中皮腫、神経膠芽腫および多発性骨髄腫からなる群から選択したものである、請求項１２に記載の薬剤。Cancer is breast cancer, colon cancer, non-small cell lung cancer, non-Hodgkin lymphoma (NHL), kidney cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma and multiple The drug according to claim 12, which is selected from the group consisting of multiple myeloma. 眼の血管新生に起因する疾患が、糖尿病性盲目、網膜症、原発性糖尿病性網膜症、加齢性黄斑変性症又はルベオーシスである、請求項１２に記載の薬剤。The drug according to claim 12, wherein the disease caused by ocular neovascularization is diabetic blindness, retinopathy, primary diabetic retinopathy, age-related macular degeneration, or rubeosis. 第二治療薬と同時に又は連続して投与される、請求項１から１４のいずれか一項に記載の薬剤。15. A medicament according to any one of claims 1 to 14, which is administered simultaneously or sequentially with a second therapeutic agent. 第二治療薬が、抗血管形成剤、抗腫瘍性組成物、化学療法剤及び細胞障害性剤からなる群から選択した作用剤である、請求項１５に記載の薬剤。16. The agent according to claim 15, wherein the second therapeutic agent is an agent selected from the group consisting of an anti-angiogenic agent, an antitumor composition, a chemotherapeutic agent and a cytotoxic agent. 第二治療薬としての抗血管形成剤が、抗体Ａ４．６．１と同じＶＥＧＦエピトープに結合することができる抗ｈＶＥＧＦ抗体である、請求項１６に記載の薬剤。The agent according to claim 16, wherein the anti-angiogenic agent as the second therapeutic agent is an anti-hVEGF antibody capable of binding to the same VEGF epitope as antibody A4.6.1. 抗体が二重特異性抗体である、請求項１から１７の何れか一項に記載の薬剤。The drug according to any one of claims 1 to 17, wherein the antibody is a bispecific antibody.
JP2010243125A 2003-08-01 2010-10-29 Anti-VEGF antibody Expired - Lifetime JP5162644B2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US49187703P 2003-08-01 2003-08-01
US60/491,877 2003-08-01
US51649503P 2003-11-01 2003-11-01
US60/516,495 2003-11-01
US57091204P 2004-05-12 2004-05-12
US60/570,912 2004-05-12
US57123904P 2004-05-13 2004-05-13
US60/571,239 2004-05-13
US57631504P 2004-06-01 2004-06-01
US60/576,315 2004-06-01
US58075704P 2004-06-18 2004-06-18
US60/580,757 2004-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006522632A Division JP4845732B2 (en) 2003-08-01 2004-07-30 Anti-VEGF antibody

Publications (3)

Publication Number Publication Date
JP2011046732A JP2011046732A (en) 2011-03-10
JP2011046732A5 true JP2011046732A5 (en) 2012-01-05
JP5162644B2 JP5162644B2 (en) 2013-03-13

Family

ID=34120173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006522632A Expired - Lifetime JP4845732B2 (en) 2003-08-01 2004-07-30 Anti-VEGF antibody
JP2010243125A Expired - Lifetime JP5162644B2 (en) 2003-08-01 2010-10-29 Anti-VEGF antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006522632A Expired - Lifetime JP4845732B2 (en) 2003-08-01 2004-07-30 Anti-VEGF antibody

Country Status (17)

Country Link
US (9) US20050106667A1 (en)
EP (2) EP2420512A3 (en)
JP (2) JP4845732B2 (en)
KR (6) KR20130098436A (en)
CN (1) CN104761643A (en)
AU (1) AU2004262006C1 (en)
BR (1) BRPI0412637A (en)
CA (2) CA2932216A1 (en)
EA (1) EA012835B1 (en)
HK (1) HK1211600A1 (en)
IL (2) IL173317A (en)
MX (1) MXPA06001319A (en)
NO (1) NO20061014L (en)
NZ (2) NZ575674A (en)
OA (1) OA13225A (en)
SG (2) SG145725A1 (en)
WO (1) WO2005012359A2 (en)

Families Citing this family (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005532253A (en) * 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド Glycoprotein composition
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003287099A1 (en) * 2002-11-08 2004-06-03 Kin-Ping Wong Extract of trapa natans and methods of using the same
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN102641503A (en) 2004-07-20 2012-08-22 健泰科生物技术公司 Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
JP2008524241A (en) * 2004-12-17 2008-07-10 ジェネンテック・インコーポレーテッド Anti-angiogenic treatment of autoimmune disease in patients who have not had the effect of conventional treatment
FR2893622B1 (en) 2005-11-24 2007-12-21 Commissariat Energie Atomique CAPROLACTAM-BASED COMPOSITION, METHOD OF MANUFACTURING SEALING ELEMENT, AND TANK
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2012204022C1 (en) * 2005-12-02 2014-02-20 Genentech, Inc. Binding polypeptides and uses thereof
CN101370832B (en) * 2005-12-02 2014-07-02 健泰科生物技术公司 Binding polypeptides and uses thereof
RU2470941C2 (en) * 2005-12-02 2012-12-27 Дженентек, Инк. Binding polypeptides and use thereof
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
JP5358187B2 (en) 2005-12-15 2013-12-04 ジェネンテック， インコーポレイテッド Methods and compositions targeting polyubiquitin
EP2402373B1 (en) 2006-01-05 2016-10-19 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
RS54156B1 (en) 2006-03-21 2015-12-31 Genentech Inc. Combinatorial therapy involving alpha5beta1 antagonists
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
KR20090027227A (en) 2006-06-06 2009-03-16 제넨테크, 인크. Anti-dll4 antibodies and methods using same
KR101136763B1 (en) * 2006-08-21 2012-04-24 에프. 호프만-라 로슈 아게 Tumor therapy with an anti-vegf antibody
PL2059533T3 (en) * 2006-08-30 2013-04-30 Genentech Inc Multispecific antibodies
PT2066694E (en) 2006-09-29 2016-01-27 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
CU23636A1 (en) 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTELIUM (VEGF)
ZA200903489B (en) * 2006-12-11 2010-08-25 Genentech Inc Compositions and methods for treating a neoplasm
EP3095455A1 (en) * 2006-12-19 2016-11-23 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
MX2009008132A (en) * 2007-02-01 2009-08-12 Genentech Inc Combination therapy with angiogenesis inhibitors.
KR20090114443A (en) 2007-02-09 2009-11-03 제넨테크, 인크. Anti-Robo4 Antibodies and Uses Therefor
WO2008103475A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US7977313B2 (en) * 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
JP2010530359A (en) 2007-05-17 2010-09-09 ジェネンテック， インコーポレイテッド Crystal structures of neuropilin fragments and neuropilin-antibody complexes
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
AU2013205269B2 (en) * 2007-11-09 2016-05-19 Affitech Research As Anti-VEGF antibody compositions and methods
BRPI0817063A2 (en) 2007-11-09 2015-03-24 Genentch Inc "Inhibition methods, for treatment of a pathological condition, for inhibition of tumor lymphagenesis, for inhibition or prevention, for disorganization, for inhibition of tumor growth, for treatment, for enhancing the efficacy of an anti-angiogenesis and antagonist agent" from alk-1
DK2219672T3 (en) * 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
AU2015200714B2 (en) * 2007-11-30 2017-01-12 Genentech, Inc. Anti-VEGF antibodies
AU2013204108B2 (en) * 2007-11-30 2014-11-20 Genentech, Inc. Anti-VEGF antibodies
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ES2414804T3 (en) 2008-01-18 2013-07-22 Genentech, Inc. Methods and compositions that target polyubiquitin
US8663643B2 (en) 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
DK2274008T3 (en) 2008-03-27 2014-05-12 Zymogenetics Inc Compositions and Methods for Inhibition of PDGFRBETA and VEGF-A
BRPI0910482A2 (en) * 2008-04-29 2019-09-24 Abbott Lab double variable domain immunoglobins and their uses
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0913406A2 (en) 2008-06-03 2018-01-09 Abbott Lab double variable domain immunoglobulins and their uses
PL2307454T3 (en) 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
EP2321433A2 (en) * 2008-08-29 2011-05-18 F. Hoffmann-La Roche AG Diagnostics and treatments for vegf-independent tumors
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102245208B (en) 2008-10-14 2016-03-16 霍夫曼-拉罗奇有限公司 immunoglobulin variants and uses thereof
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
HUE024872T2 (en) 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
KR101596539B1 (en) 2008-12-23 2016-02-22 제넨테크, 인크. Methods and compositions for diagnostic use in cancer patients
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
EP2414391B1 (en) * 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (en) 2009-04-07 2015-04-29 Roche Glycart Ag Trivalent, bispecific antibodies
KR20120096401A (en) * 2009-04-20 2012-08-30 제넨테크, 인크. Adjuvant cancer therapy
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2766403A1 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AR077595A1 (en) 2009-07-27 2011-09-07 Genentech Inc COMBINATION TREATMENTS
RU2567803C2 (en) 2009-07-31 2015-11-10 Дженентек, Инк. INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS
JP5756802B2 (en) * 2009-08-13 2015-07-29 クリスタル バイオサイエンス インク．Ｃｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． Transgenic animals producing antibodies with minimal CDRs
JP2013501526A (en) 2009-08-14 2013-01-17 ジェネンテック， インコーポレイテッド Biological markers for monitoring patient response to VEGF antagonists
SG178419A1 (en) 2009-08-15 2012-04-27 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN102612524A (en) 2009-09-01 2012-07-25 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
MX2012002862A (en) 2009-09-11 2012-08-15 Genentech Inc Method to identify a patient with an increased likelihood of responding to an anti-cancer agent.
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
EP2486408A4 (en) * 2009-10-05 2013-04-24 Opsonic Therapeutics Inc High affinity adaptor molecules for redirecting antibody specifity
CN102666875A (en) 2009-10-15 2012-09-12 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
WO2011050034A1 (en) * 2009-10-21 2011-04-28 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2781682A1 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
ES2565208T3 (en) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anti-VEGF-C antibodies and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
SG10201705886SA (en) 2009-12-21 2017-08-30 Genentech Inc Antibody formulation
MY161868A (en) 2009-12-23 2017-05-15 Genentech Inc Anti-bv8 antibodies and uses thereof
WO2011088111A1 (en) * 2010-01-12 2011-07-21 Genentech, Inc. ANTI-PlGF ANTIBODIES AND METHODS USING SAME
KR20180028561A (en) 2010-02-23 2018-03-16 제넨테크, 인크. Anti-angiogenesis therapy for the treatment of ovarian cancer
CN102167740B (en) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 Fully human anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody and preparation method as well as application thereof
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
AR080794A1 (en) * 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
CA2793503A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
AU2011281702A1 (en) 2010-07-19 2013-01-31 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
MX2013000667A (en) 2010-07-19 2013-02-27 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
US20130177500A1 (en) 2010-07-23 2013-07-11 Trustee Of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR082693A1 (en) 2010-08-17 2012-12-26 Roche Glycart Ag COMBINATION THERAPY OF AN ANTI-CD20 AFUCOSILATED ANTIBODY WITH AN ANTI-VEGF ANTIBODY
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
RU2013113225A (en) 2010-08-26 2014-10-10 Эббви Инк. IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
KR20130103734A (en) 2010-08-31 2013-09-24 제넨테크, 인크. Biomarkers and methods of treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SG189835A1 (en) * 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Antibodies
TW201300417A (en) 2010-11-10 2013-01-01 Genentech Inc Methods and compositions for neural disease immunotherapy
BR112013012040A2 (en) 2010-11-15 2016-08-16 Five Prime Therapeutics Inc high-dose cancer treatment of soluble fdfr1 fusion proteins
EP2643351A1 (en) * 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CU23895B1 (en) 2010-12-28 2013-05-31 Biorec Sa RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTHELIUM (VEGF) OBTAINED BY MUTAGENESIS OF VARIABLE REGIONS
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
HUE053720T2 (en) 2011-01-14 2021-07-28 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
CA2826142A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
ES2549638T3 (en) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Antigen binding proteins
CN103476795B (en) 2011-03-29 2016-07-06 罗切格利卡特公司 Antibody Fc variant
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
JP2014513128A (en) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド Vascular disruptors and their use
SG194932A1 (en) 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9103754B2 (en) 2011-08-01 2015-08-11 Denovo Sciences, Inc. Cell capture system and method of use
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
WO2013022848A1 (en) 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
KR20140068877A (en) 2011-08-17 2014-06-09 제넨테크, 인크. Inhibition of angiogenesis in refractory tumors
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
HRP20230078T1 (en) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
JP2014533700A (en) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド Purification of anti-c-MET antibody
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
JP2015502543A (en) 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Plasma biomarker for bevacizumab combination therapy for breast cancer treatment
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17
WO2013106765A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
JP6563197B2 (en) 2012-03-13 2019-08-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy for the treatment of ovarian cancer
MX2014011582A (en) 2012-03-30 2014-11-21 Genentech Inc Diagnostic methods and compositions for treatment of cancer.
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
TWI641687B (en) * 2012-05-29 2018-11-21 美商再生元醫藥公司 Production cell line enhancers
KR20200079568A (en) 2012-05-31 2020-07-03 제넨테크, 인크. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407537YA (en) 2012-06-08 2014-12-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2013188403A1 (en) * 2012-06-11 2013-12-19 Syngenta Participations Ag Producing solids and related mother liquors
WO2014001232A1 (en) 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
JP6309002B2 (en) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Methods and uses for making antibody Fc region conjugates comprising at least one binding entity that specifically binds to a target
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
NZ702201A (en) 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150036274A (en) 2012-07-19 2015-04-07 알레시아 바이오쎄라퓨틱스 인코포레이티드 Anti-siglec-15 antibodies
CN104507498A (en) 2012-08-07 2015-04-08 霍夫曼-拉罗奇有限公司 Combination therapy for the treatment of glioblastoma
WO2014028446A1 (en) * 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
WO2014043480A1 (en) 2012-09-13 2014-03-20 Crystal Ronald G Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
UY35110A (en) 2012-11-01 2014-05-30 Abbvie Inc ANTI-VEGF / DLL4 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THE SAME
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
PT2956476T (en) 2013-02-18 2020-02-21 Vegenics Pty Ltd Ligand binding molecules and uses thereof
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
MX2015011428A (en) 2013-03-06 2016-02-03 Genentech Inc Methods of treating and preventing cancer drug resistance.
AU2014243783B2 (en) 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
AU2014250940A1 (en) 2013-04-09 2015-10-22 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2016524611A (en) 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク How to treat cancer
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
KR101541478B1 (en) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 Anti-vegf antibodies and pharmaceutical composition comprising same for preventing, diagnosing or treating cancer or angiogenesis-related disease
KR20160042438A (en) 2013-08-12 2016-04-19 제넨테크, 인크. Compositions and method for treating complement-associated conditions
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
PL3041513T3 (en) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
KR20220013459A (en) 2013-10-25 2022-02-04 악셀레론 파마 인코포레이티드 Endoglin peptides to treat fibrotic diseases
WO2015081290A1 (en) 2013-11-27 2015-06-04 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
US20160130336A1 (en) * 2013-12-31 2016-05-12 Development Center For Biotechnology Anti-vegf antibodies and use thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
TWI558399B (en) 2014-02-26 2016-11-21 美國禮來大藥廠 Combination therapy for cancer
TW201622744A (en) 2014-03-04 2016-07-01 美國禮來大藥廠 Combination therapy for cancer
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
BR112016021383A2 (en) 2014-03-24 2017-10-03 Genentech Inc METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
TW201623337A (en) 2014-05-01 2016-07-01 建南德克公司 Anti-Factor D antibody variants and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP2017517552A (en) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド Treatment and prevention of anticancer drug resistance
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106460067A (en) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 Diagnostic methods and compositions for treatment of glioblastoma
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
RU2704611C2 (en) 2014-09-15 2019-10-30 Дженентек, Инк. Antibody-based formulations
CN107106687A (en) 2014-10-03 2017-08-29 诺华股份有限公司 Combined therapy
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
MA40035A (en) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc PD-L1 ANTIBODY MOLECULES AND THEIR USES
KR102210104B1 (en) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
TWI705976B (en) 2014-11-10 2020-10-01 美商建南德克公司 Anti-interleukin-33 antibodies and uses thereof
CN107250158B (en) 2014-11-19 2022-03-25 基因泰克公司 Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use
EP3845565A3 (en) 2014-11-19 2021-09-08 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
CN107001482B (en) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JP2018508183A (en) 2014-12-23 2018-03-29 ジェネンテック， インコーポレイテッド Compositions and methods for treating and diagnosing chemotherapy-resistant cancer
CN114716550A (en) 2015-05-12 2022-07-08 Synt免疫公司 Humanized affinity matured anti-FcRn antibodies
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
TW201711702A (en) 2015-06-04 2017-04-01 應克隆公司 Therapies utilizing compounds to fibroblast growth factor receptor-3 (FGFR3)
CA2988420A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
TW201716439A (en) 2015-07-20 2017-05-16 美國禮來大藥廠 HER3 antibodies
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
KR20180053315A (en) 2015-09-23 2018-05-21 제넨테크, 인크. Optimized variants of anti-VEGF antibodies
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
US20170137535A1 (en) 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
BR112018008867A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
US11007259B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. High-affinity anti-VEGF antibody
US11008387B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. Antibody inhibiting binding of VEGF to NRP1
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
EP3443350B1 (en) 2016-04-15 2020-12-09 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
EP3442573A1 (en) 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
CN108883182A (en) 2016-04-15 2018-11-23 伊莱利利公司 For treating the combined therapy of the thunder of lymphoma mantle cell not Lu Dankang and ABEMACICLIB
JP7050001B2 (en) 2016-04-25 2022-04-07 シンティミューン，インコーポレイティド Humanized affinity matured anti-FCRN antibody
JP2019517507A (en) 2016-06-03 2019-06-24 イムクローン リミテッド ライアビリティ カンパニー Combination of Rumsylumab and Pembrolizumab for the Treatment of Specific Cancers
EP3481946A1 (en) 2016-07-07 2019-05-15 The European Molecular Biology Laboratory Viral polypeptide fragments that bind cellular pol ii c-terminal domain (ctd) and their uses
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
CN109690315A (en) 2016-07-08 2019-04-26 豪夫迈·罗氏有限公司 People's epididymal proteins 4 (HE4) are used to assess the purposes of the responsiveness of MUC16 positive cancer treatment
CN109477843A (en) 2016-07-15 2019-03-15 豪夫迈·罗氏有限公司 For detecting the horizontal ways and means of total VEGF-A
JPWO2018030193A1 (en) * 2016-08-08 2019-06-06 コニカミノルタ株式会社 Methods for assessment of tumor tissue in experimental animals
US11254738B2 (en) 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
KR102242990B1 (en) 2016-09-29 2021-04-22 북경한미약품 유한공사 Heterodimeric immunoglobulin structure and preparation method thereof
WO2018081512A1 (en) 2016-10-28 2018-05-03 Imclone Llc Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancer
CN109952315A (en) 2016-11-16 2019-06-28 伊莱利利公司 Treatment for metastatic colorectal carcinoma
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
WO2018090950A1 (en) 2016-11-18 2018-05-24 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
JP7106563B2 (en) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Naphthofuran derivatives, their preparation and methods of use
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
KR20190134631A (en) 2017-03-01 2019-12-04 제넨테크, 인크. How to diagnose and treat cancer
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
KR20190138636A (en) 2017-03-22 2019-12-13 제넨테크, 인크. Optimized Antibody Compositions for the Treatment of Eye Disorders
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
JP7433910B2 (en) 2017-06-22 2024-02-20 ノバルティス アーゲー Antibody molecules against CD73 and uses thereof
EP4039367A1 (en) 2017-08-29 2022-08-10 Bio-Rad Laboratories, Inc. System and method for isolating and analyzing cells
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
CN107727847A (en) * 2017-09-30 2018-02-23 安徽伊普诺康生物技术股份有限公司 A kind of blood vessel endothelial factor detection kit and its application method
CN107703290A (en) * 2017-09-30 2018-02-16 安徽伊普诺康生物技术股份有限公司 A kind of preparation method of blood vessel endothelial factor detection kit
EP3715844A4 (en) 2017-11-20 2021-04-14 Konica Minolta, Inc. Drug evaluation method
WO2019153200A1 (en) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
WO2019154349A1 (en) 2018-02-11 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
SG11202009267QA (en) * 2018-03-19 2020-10-29 Pharmabcine Inc Anti-vegfr-2 antibody
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN111989095A (en) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 Method for preventing or treating side effects of tumor therapy
US11746157B2 (en) 2018-05-24 2023-09-05 Janssen Biotech, Inc. PSMA binding agents and uses thereof
WO2019225787A1 (en) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 Anti-b7-h3 antibody and use thereof
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
EA202191656A1 (en) 2018-12-21 2021-10-26 23Эндми, Инк. ANTI-IL-36 ANTIBODIES AND METHODS OF THEIR APPLICATION
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
AR118720A1 (en) 2019-04-19 2021-10-27 Janssen Biotech Inc METHODS FOR TREATING PROSTATE CANCER WITH AN ANTI-PSMA / CD3 ANTIBODY
EP3962947A2 (en) 2019-05-03 2022-03-09 F. Hoffmann-La Roche AG Methods of treating cancer with an anti-pd-l1 antibody
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
KR20220016477A (en) 2019-05-07 2022-02-09 바이오 래드 래버러토리스 인코오포레이티드 Systems and Methods for Automated Single Cell Processing
US20230074615A1 (en) * 2019-05-21 2023-03-09 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
JP2022539739A (en) * 2019-06-26 2022-09-13 バイオ－ラッド ラボラトリーズ インコーポレイテッド Target substance recovery system and method from microwells
WO2020260595A1 (en) 2019-06-26 2020-12-30 Oncurious Nv Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
BR112022001017A2 (en) 2019-07-19 2022-04-12 Sinocelltech Ltd Humanized anti-vegf monoclonal antibody
WO2021013065A1 (en) * 2019-07-19 2021-01-28 神州细胞工程有限公司 Humanized anti-vegf fab antibody fragment and use thereof
WO2021013785A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a9 as blood biomarker for the non-invasive diagnosis of endometriosis
EP4004555A1 (en) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis
CN114144674A (en) 2019-07-22 2022-03-04 豪夫迈·罗氏有限公司 Substance P as a blood biomarker for the non-invasive diagnosis of endometriosis
JP7421631B2 (en) 2019-07-22 2024-01-24 エフ． ホフマン－ラ ロシュ アーゲー S100A8 as a blood biomarker for non-invasive diagnosis of endometriosis
EP4004552A1 (en) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a12 as blood biomarker for the non-invasive diagnosis of endometriosis
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
KR20220100883A (en) 2019-11-15 2022-07-18 에프. 호프만-라 로슈 아게 Derivatization of Beta-Lactam Antibiotics for Mass Spectrometry Determination of Patient Samples
CN114901700A (en) * 2019-11-21 2022-08-12 尤尼蒂生物技术公司 Antibodies to TIE-2 and methods of use thereof
KR20220152262A (en) 2020-03-13 2022-11-15 제넨테크, 인크. Anti-interleukin-33 antibodies and uses thereof
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023520515A (en) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods for cancer
US20230120988A1 (en) 2020-04-23 2023-04-20 Roche Diagnostics Operations, Inc. Corona nucleocapsid antigen for use in antibody-immunoassays
CR20220608A (en) 2020-05-29 2023-01-26 23Andme Inc Anti-cd200r1 antibodies and methods of use thereof
US20230235040A1 (en) 2020-06-22 2023-07-27 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP3943946A1 (en) 2020-07-20 2022-01-26 F. Hoffmann-La Roche AG Gdf-15 for predicting the disease severity of a patient with covid-19
JP2023541627A (en) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Antibodies that bind to IL1RAP and uses thereof
WO2022090455A1 (en) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Sars-cov-2 nucleocapsid antibodies
TW202224682A (en) 2020-11-13 2022-07-01 美商建南德克公司 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
JP2024500326A (en) 2020-12-08 2024-01-09 ジェネンテック， インコーポレイテッド Methods and compositions comprising KRASG12C inhibitors and EGFR inhibitors for treating solid tumors
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
US20240052045A1 (en) 2020-12-24 2024-02-15 Vib Vzw Murine cross-reactive human ccr8 binders
US20220249639A1 (en) 2021-01-22 2022-08-11 Dcprime B.V. Methods of tumor vaccination
JP2024504758A (en) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド PSMA binding protein and its use
AR124914A1 (en) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp NEW ANTI-PAD4 ANTIBODY
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
CN112961243B (en) * 2021-03-24 2022-04-29 山东兴瑞生物科技有限公司 VEGF antibody, recombinant AAV (adeno-associated Virus) and application thereof
WO2022207628A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf as blood biomarker for the non-invasive diagnosis of endometriosis
EP4314838A1 (en) 2021-04-01 2024-02-07 F. Hoffmann-La Roche AG Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
EP4341700A1 (en) 2021-05-17 2024-03-27 F. Hoffmann-La Roche AG Sfrp4 as blood biomarker for the non-invasive diagnosis of adenomyosis
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
EP4363449A2 (en) 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
CN117715936A (en) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 Methods and compositions for treating cancer
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023144973A1 (en) 2022-01-27 2023-08-03 中外製薬株式会社 Pharmaceutical composition containing anti-pd-l1 antibody to be used in combination with anti-vegf antibody and paclitaxel
WO2023142996A1 (en) 2022-01-28 2023-08-03 上海岸阔医药科技有限公司 Method for preventing or treating disease or disorder associated with antineoplastic agent
CN116925234B (en) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 AAV vector for encoding anti-VEGF-A and ANG-2 bispecific antibody
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023213758A1 (en) 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Hiv gp41 variants for immunodiagnostic assays
WO2023247752A1 (en) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Method for diagnosing endometriosis and for classifying the stage of endometriosis
WO2024017982A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017983A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017985A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Fibroblast growth factor binding protein 1 (fgfbp1) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
CN115850470B (en) * 2022-12-12 2023-07-07 三门峡市眼科医院 VEGF antibodies and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
FR2596047B1 (en) 1986-03-21 1988-05-13 Charbonnages Ste Chimique PROCESS FOR PRODUCING STYRENE
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
DE68913658T3 (en) 1988-11-11 2005-07-21 Stratagene, La Jolla Cloning of immunoglobulin sequences from the variable domains
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE164395T1 (en) * 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69232137T2 (en) 1991-11-25 2002-05-29 Enzon Inc MULTIVALENT ANTI-BINDING PROTEINS
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2112431T3 (en) 1992-08-21 1998-04-01 Genentech Inc PROCEDURE FOR THE TREATMENT OF AN LFA-1 MEDIATED DISORDER.
PT752248E (en) 1992-11-13 2001-01-31 Idec Pharma Corp THERAPEUTIC APPLICATION OF QUIMERIC ANTIBODIES AND RADIOACTIVELY MARKING OF ANTIGENES OF RESTRICTED DIFFERENTIATION OF HUMAN LYMPHOCYTE B FOR THE TREATMENT OF B-CELL LYMPHOMA
JP3720353B2 (en) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5650727A (en) * 1995-04-07 1997-07-22 Wizaed Devices, Inc. Circuit continuity testing device
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP4318752B2 (en) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド Anti-endoglin monoclonal antibody and its use in anti-angiogenic therapy
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CA2286330C (en) 1997-04-07 2008-06-10 Genentech, Inc. Anti-vegf antibodies
US6190908B1 (en) * 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
EP1230552B1 (en) 1999-11-16 2006-01-11 Genentech, Inc. Elisa for vegf
CN1299833A (en) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 Human vessel endothelium growth factor resisting single stranded antibody and its preparation
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2002252631A1 (en) 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DK1385864T3 (en) * 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2 antibodies
CN1187373C (en) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 Human resourced monoclone antibody of anti-blood-vessel endothelium growth factor as well as its preparing method and medicine composition
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
KR20160014775A (en) * 2003-05-30 2016-02-11 제넨테크, 인크. Treatment with anti-VEGF antibodies
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TWI580694B (en) * 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
WO2010027981A1 (en) * 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
DK2488867T3 (en) 2009-10-14 2020-11-09 Janssen Biotech Inc PROCEDURES FOR AFFINITY MATURE OF ANTIBODIES
WO2013022848A1 (en) 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2011046732A5 (en)
JP2018070648A5 (en)
JP2018536632A5 (en) Molecules that specifically bind to B7-H3 and molecules that specifically bind to PD-1
JP2018536624A5 (en)
IL266756A (en) Human monoclonal antibodies binding to masp-2 and inhibiting masp-2 dependent complement activation, methods of producing same and uses thereof
JP2020504723A5 (en)
JP2017535257A5 (en)
JP2012530496A5 (en)
JP2018503380A5 (en)
JP2014522850A5 (en)
JP2016512551A5 (en)
JP2015520758A5 (en)
JP2015509948A5 (en)
JP2014511179A5 (en)
JP2016508496A5 (en)
JP2018500014A5 (en)
JP2016538318A5 (en)
JP2017514795A5 (en)
JP2016505546A5 (en)
JP2013519364A5 (en)
JP2016536020A5 (en)
JP2015534577A5 (en)
CL2013003373A1 (en) B binding protein to the b-cell maturation antigen (bcma); pharmaceutical composition comprising the protein; use to prepare a useful medication to treat multiple myeloma or (mm) chronic lymphocytic leukemia (cll).
JP2015509947A5 (en)
JP2015534579A5 (en)